BTC Health Ltd Announces Arna Pharma's Voluntary Administration
Key points
- Arna Pharma, a manufacturer of Bronchitol® and Aridol®, entered voluntary administration on 7 September 2026
- BTC Health, parent company of BTC Pharma, is not financially exposed to Arna Pharma
- BTC Pharma holds eight months of Bronchitol® stock and less than one month of Aridol® stock
- BTC Health expects sales of Aridol® and Bronchitol® to drop to $0.5 million in FY2027
Full summary
BTC Health Limited (ASX: BTC) has announced that Arna Pharma Pty Ltd, the manufacturer of Bronchitol® and Aridol®, has entered voluntary administration. This development follows the appointment of administrators by Arna Pharma's board. BTC Pharma, a wholly-owned subsidiary of BTC Health, is the Australian sponsor of both products and holds the exclusive distribution rights. BTC Pharma currently holds approximately eight months of Bronchitol® stock and less than one month of Aridol® stock. BTC Health expects sales of these products to drop to up to $0.5 million in FY2027 without further supply. BTC Pharma is engaging with the administrators and relevant authorities to ensure continuity of supply.
Guidance
BTC Health expects sales of Aridol® and Bronchitol® to be up to $0.5 million in FY2027.
Outlook
Arna Pharma has stated its intention to recapitalize the business and maintain continuity of supply, though BTC Health cannot verify this position.
Summary generated by a large language model. Please interpret with care.